Table 2 Differences in demographic and clinical characteristics among the employment interference latent classes at enrollment
Characteristic | None (0) 26.2% (n = 101) | Low (1) 42.6% (n = 164) | High (2) 31.2% (n = 120) | Statistics |
|---|---|---|---|---|
Mean (SD) | Mean (SD) | Mean (SD) | ||
Age (years) | 62.4 (11.4) | 54.8 (10.3) | 48.7 (9.5) | F = 48.04, p < 0.001 0 > 1 > 2 |
Education (years) | 15.0 (2.6) | 16.1 (2.5) | 15.9 (2.7) | F = 5.46, p = 0.005 0 < 1 and 2 |
Self-Administered Comorbidity Questionnaire score | 4.8 (2.9) | 3.8 (2.8) | 4.3 (2.7) | F = 3.90, p = 0.021 0 > 1 |
Karnofsky Performance Status score | 95.7 (8.0) | 93.2 (10.7) | 91.3 (11.0) | F = 5.17, p = 0.006 0 > 2 |
Body mass index (kg/m2) | 27.5 (6.7) | 26.1 (5.6) | 27.4 (6.2) | F = 2.46, p = 0.086 |
| Â | % (n) | % (n) | % (n) | Â |
Ethnicity – Non-White | 30.7 (31) | 26.2 (43) | 47.5 (57) | X2 = 14.66, p = 0.001 0 and 1 < 2 |
Married/partnered (% yes) | 41.6 (42) | 38.4 (63) | 45.0 (54) | X2 = 1.24, p = 0.537 |
Lives alone (% yes) | 27.7 (28) | 22.6 (37) | 20.8 (25) | X2 = 1.56, p = 0.459 |
Currently employed (% yes) | 16.8 (17) | 68.9 (113) | 48.3 (58) | X2 = 67.85, p < 0.001 0 < 1 and 2, 1 > 2 |
Number of work hours per week (% yes) | X2 = 1.43, p = 0.838 | |||
 1–35 h/week | 38.9 (7) | 36.3 (41) | 44.8 (26) | |
 36–44 h/week | 44.4 (8) | 48.7 (55) | 39.7 (23) | |
 45h hours/week | 16.7 (3) | 15.0 (17) | 15.5 (9) | |
Annual household income | KW, p < 0.001 0 < 1, 1 > 2 | |||
  < $30,000a | 23.1 (18) | 10.3 (15) | 34.4 (33) | |
 $30,000 to <$70,000 | 28.2 (22) | 24.0 (35) | 25.0 (24) |  |
 $70,000 to <$100,000 | 14.1 (11) | 20.5 (30) | 10.4 (10) | |
  > $100,000 | 34.6 (27) | 45.2 (66) | 30.2 (29) | |
Gone through menopause prior to surgery (% yes) | 79.2 (80) | 65.9 (108) | 50.8 (61) | X2 = 19.50, p < 0.001 0 and 1 > 2 |
Days since cancer diagnosis (mean (SD)) | 57.3 (63.9) | 67.7 (83.7) | 84.8 (77.0) | KW, p = 0.079 |
Days since cancer diagnosis (median) | 39.0 | 36.0 | 40.50 | |
Stage of disease | KW, p < 0.001 0 and 1 < 2 | |||
 Stage 0 | 16.8 (17) | 23.8 (39) | 14.2 (17) | |
 Stage I | 53.5 (54) | 37.2 (61) | 26.7 (32) | |
 Stage IIa and IIb | 25.7 (26) | 32.9 (54) | 45.8 (55) | |
 Stage IIIa, IIIb, IIIc, and IVa | 4.0 (4) | 6.1 (10) | 13.3 (16) | |
Type of surgery | X2 = 6.84, p = 0.033 No significant post hoc contrasts | |||
 Breast conservation | 85.1 (86) | 74.4 (122) | 85.0 (102) | |
 Mastectomy | 14.9 (15) | 25.6 (42) | 15.0 (18) | |
 Sentinel lymph node biopsy (% yes) | 84.2 (85) | 84.8 (139) | 79.2 (95) | X2 = 1.69, p = 0.430 |
 Axillary lymph node dissection (% yes) | 23.8 (24) | 31.7 (52) | 54.2 (65) | X2 = 24.82, p < 0.001 0 and 1 < 2 |
 Underwent reconstruction at the time of surgery (% yes) | 14.9 (15) | 25.0 (41) | 23.3 (28) | X2 = 4.01, p = 0.135 |
 Received neoadjuvant therapy (% yes) | 11.9 (12) | 17.7 (29) | 30.8 (37) | X2 = 13.37, p = 0.001 0 and 1 < 2 |
 Pain in the affected breast prior to surgery (% yes) | 20.8 (21) | 27.4 (45) | 31.7 (38) | X2 = 3.32, p = 0.191 |
 Received radiation therapy during the 12 months following surgery (% yes) | 68.3 (69) | 70.1 (115) | 75.0 (90) | X2 = 1.35, p = 0.510 |
 Received chemotherapy during the 12 months following surgery (% yes) | 26.7 (27) | 29.9 (49) | 45.8 (55) | X2 = 11.10, p = 0.004 0 and 1 < 2 |
 Received hormonal therapy during the 12 months following surgery (% yes) | 64.4 (65) | 61.0 (100) | 55.8 (67) | X2 = 1.73, p = 0.422 |
 Received complementary therapy in the 12 months following surgery (% yes) | 19.8 (20) | 39.6 (65) | 36.7 (44) | X2 = 11.82, p = 0.003 0 < 1 and 2 |
 Had breast reconstruction in the 12 months following surgery (% yes) | 7.9 (8) | 14.6 (24) | 11.7 (14) | X2 = 2.69, p = 0.260 |
 Had re-excision or mastectomy on the affected breast in the six months following surgery (% yes) | 24.8 (25) | 25.6 (42) | 41.7 (50) | X2 = 10.50, p = 0.005 0 and 1 < 2 |